Skip to content

Study · Not a test of the peptide alone · 2015

4 results

Comparative Resistance to Teriparatide-Induced Bone Resorption With Denosumab or Alendronate.

Tsai JN, Zhu Y, Foley K, Lee H, Burnett-Bowie SA, Neer RM, Leder BZ

The Journal of clinical endocrinology and metabolism1 May 2015Cited by 6 (Europe PMC)

PMID25933031 (opens in a new tab)PMCIDPMC5393530 (opens in a new tab)DOI10.1210/jc.2015-1541 (opens in a new tab)PepBankPUB-25933031
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 01HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialMechanism

    In postmenopausal women, denosumab suppressed the CTX response to a teriparatide challenge more than alendronate after eight weeks.

    In plain wordsIn women, denosumab suppressed the bone resorption response to a teriparatide challenge more than alendronate.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseBetween-group CTX response after antiresorptive treatment
    Study

    n = 25

    Comparator
    Alendronate
    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    CTX increase
    43%
    after alendronate
    CTX change
    −7%
    after denosumab

    Source sentences

    Summary
    After 8 weeks, teriparatide was still able to stimulate bone resorption in women treated with alendronate (mean CTX increase of 43% ± 29%) but not in women treated with denosumab (-7% ± 11%; P < .001 for between group comparison).
    4 context sentences
    Summary · context
    The primary outcome was the between-group difference in the teriparatide-induced change in CTX from baseline to week 8.
    Summary · context
    In this randomized controlled trial, bone resorption (serum C-telopeptide [CTX]) was measured in 25 postmenopausal women prior to and 4 hours after a single 40-μg sc teriparatide injection.
    Summary · context
    Subjects then received either a single injection of denosumab 60 mg or oral alendronate 70 mg weekly for 8 weeks.
    Summary · context
    After 8 weeks, serum CTX was again measured before and 4 hours after a teriparatide a 40-μg injection.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  2. 02HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialMechanism

    In postmenopausal women before antiresorptive treatment, a single 40-μg teriparatide injection increased CTX by 47% in the group later given alendronate and 46% in the group later given denosumab.

    In plain wordsIn women before any bone drug, a teriparatide challenge raised a bone resorption marker by similar amounts in both groups.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseBaseline teriparatide-induced CTX increase
    Study

    n = 25

    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    CTX increase
    47%
    baseline challenge, alendronate group
    CTX increase
    46%
    baseline challenge, denosumab group

    Source sentences

    Summary
    At baseline, 40 μg of teriparatide induced similar 4-hour increases in mean CTX in both groups (alendronate 47% ± 14%, denosumab 46% ± 16%).
    3 context sentences
    Summary · context
    In this randomized controlled trial, bone resorption (serum C-telopeptide [CTX]) was measured in 25 postmenopausal women prior to and 4 hours after a single 40-μg sc teriparatide injection.
    Summary · context
    Subjects then received either a single injection of denosumab 60 mg or oral alendronate 70 mg weekly for 8 weeks.
    Summary · context
    After 8 weeks, serum CTX was again measured before and 4 hours after a teriparatide a 40-μg injection.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  3. 03HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialMechanism

    In postmenopausal women treated with alendronate for eight weeks, the teriparatide challenge still increased CTX by 43%.

    In plain wordsIn women treated with alendronate, the teriparatide challenge still increased a bone resorption marker.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseCTX response after alendronate
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    CTX increase
    43%
    challenge after alendronate

    Source sentences

    Summary
    After 8 weeks, teriparatide was still able to stimulate bone resorption in women treated with alendronate (mean CTX increase of 43% ± 29%) but not in women treated with denosumab (-7% ± 11%; P < .001 for between group comparison).
    3 context sentences
    Summary · context
    In this randomized controlled trial, bone resorption (serum C-telopeptide [CTX]) was measured in 25 postmenopausal women prior to and 4 hours after a single 40-μg sc teriparatide injection.
    Summary · context
    Subjects then received either a single injection of denosumab 60 mg or oral alendronate 70 mg weekly for 8 weeks.
    Summary · context
    After 8 weeks, serum CTX was again measured before and 4 hours after a teriparatide a 40-μg injection.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  4. 04HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialMechanism

    In postmenopausal women treated with denosumab, the teriparatide challenge did not stimulate bone resorption after eight weeks.

    In plain wordsIn women treated with denosumab, the teriparatide challenge did not stimulate bone resorption.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeCTX response after denosumab
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    CTX change
    −7%
    challenge after denosumab

    Source sentences

    Summary
    After 8 weeks, teriparatide was still able to stimulate bone resorption in women treated with alendronate (mean CTX increase of 43% ± 29%) but not in women treated with denosumab (-7% ± 11%; P < .001 for between group comparison).
    3 context sentences
    Summary · context
    In this randomized controlled trial, bone resorption (serum C-telopeptide [CTX]) was measured in 25 postmenopausal women prior to and 4 hours after a single 40-μg sc teriparatide injection.
    Summary · context
    Subjects then received either a single injection of denosumab 60 mg or oral alendronate 70 mg weekly for 8 weeks.
    Summary · context
    After 8 weeks, serum CTX was again measured before and 4 hours after a teriparatide a 40-μg injection.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4Results postedNCT01750086

Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption

Massachusetts General Hospitaln = 27Jan 2013 to Aug 2014

Postmenopausal Osteoporosis

Trial pageClinicalTrials.govUpdated 27 Mar 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.